Loading
institutionsInstitution
University Hospital Zurich / Comprehensive Cancer Center Zurich
Zurich's university hospital and cancer centre, a world reference in neuro-oncology, melanoma and single-cell tumour imaging.
Also called: USZCCCZUniversitätsSpital Zürich
Overview
The Comprehensive Cancer Center Zurich brings together the University Hospital Zurich, the University of Zurich and ETH Zurich. Michael Weller's neurology department chairs the EORTC Brain Tumor Group and shapes glioma guidelines, and Zurich was a leading site in the glioblastoma trials that introduced temozolomide and tumour-treating fields. Reinhard Dummer's dermatology clinic is one of Europe's foremost melanoma centres and led oncolytic virus and targeted therapy studies, Bernd Bodenmiller's laboratory developed imaging mass cytometry for spatial single-cell tumour analysis, and the haematology and nuclear medicine departments run CAR-T and theranostics programmes. The centre is OECI-accredited and hosts a large early-phase unit.
Location
Zurich, CH
Type
hospital · University of Zurich
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#124 · 36 points (0 Newsweek + 0 NCI + 36 from 18 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-17.
Matched to University Hospital Zurich, including child institutions. 835 works · 10,668 citations · 82% open access · 10% clinical trials · 3% reviews.
Oncology works per year
1732022
1902023
1672024
1962025
1092026
Most works
- Reinhard Dummer58 works
- Markus G. Manz40 works
- Michael Weller40 works
- Georgina V. Long36 works
- Matthias Gückenberger34 works
- Nicole Lindenblatt28 works
- Paolo A. Ascierto28 works
- Joanna Mangana27 works
- Mitchell P. Levesque26 works
- Lara Valeska Maul25 works
Most cited
- Neuro-oncology (EORTC Brain Tumor Group)
- Melanoma and dermato-oncology
- Imaging mass cytometry
- CAR-T and haematology
- Theranostics
Markus G. Manz
Representative of University Hospital Zurich / Comprehensive Cancer Center Zurich to the Organisation of European Cancer Institutes
Cancer centre representation (OECI)
Markus G. Manz represents University Hospital Zurich / Comprehensive Cancer Center Zurich in the Organisation of European Cancer Institutes, which lists the centre among its members in Switzerland.
Monika Jänicke
CEO, Chair of the Hospital Executive Board
Hospital managementHealthcare leadership
Chief Executive Officer of University Hospital Zurich, home of the Comprehensive Cancer Center Zurich.
Reinhard Dummer
Professor of Dermatology and Vice Chairman, Department of Dermatology, University Hospital Zurich
MelanomaBRAF/MEK targeted therapyOncolytic virus therapy
Swiss dermato-oncologist who led COLUMBUS and the neoadjuvant talimogene laherparepvec studies.
Rolf A. Stahel
President, ETOP IBCSG Partners Foundation; Emeritus Professor of Oncology, University of Zurich
Thoracic oncologyAcademic cooperative trialsMesothelioma
Founded the European Thoracic Oncology Platform and leads the merged ETOP IBCSG academic trials foundation.
Michael Weller
Chair, Department of Neurology, University Hospital Zurich; Chair, EORTC Brain Tumor Group
Neuro-oncologyGliomaClinical trials
Neuro-oncologist who leads the EORTC Brain Tumor Group and co-authors the European glioma guidelines.
Similar pages
- TrialEF-14
Shares Novocure, Optune / Optune Pax (TTFields), Tumour treating fields (TTFields), Glioma & glioblastoma.
- TrialSTELLAR
Shares Novocure, Optune / Optune Pax (TTFields), Tumour treating fields (TTFields).
- PersonRoger Stupp
Shares Optune / Optune Pax (TTFields), Tumour treating fields (TTFields), EORTC, Glioma & glioblastoma.
- InstitutionRobert H. Lurie Comprehensive Cancer Center of Northwestern University
Shares Novocure, Optune / Optune Pax (TTFields), Tumour treating fields (TTFields), Glioma & glioblastoma.
- Key paperStupp 2005: temozolomide added to radiotherapy for newly diagnosed glioblastoma
Shares Michael Weller, Tumour treating fields (TTFields), EORTC, Glioma & glioblastoma.
- PairingOncolytic virus + PD-1 blockade
Shares Talimogene laherparepvec, Oncolytic viruses, Melanoma, Immune checkpoint inhibitors.
- TrialPANOVA-3
Shares Novocure, Optune / Optune Pax (TTFields), Tumour treating fields (TTFields).
- Key paperTumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study
Shares Novocure, Optune / Optune Pax (TTFields), Tumour treating fields (TTFields).
cancers
fronts
technologies
drugs
ApprovedDevice (tumour treating fields)
Optune / Optune Pax (TTFields) · Optune
ApprovedOncolytic virus (HSV-1)
Talimogene laherparepvec · Imlygic